SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma to acquire additional 20% stake in Tergene Biotech

10 Aug 2017 Evaluate

Aurobindo Pharma has entered into agreement to acquire 20% additional equity stake in Tergene Biotech. As agreed among the JV Partners, the company will increase its stake in Tergene Biotech from 60% to 80% by subscribing additional 56,50,000 equity shares of Rs 10 each at par aggregating to Rs 5.65 crore. As on date, the company acquired 3.25% and will continue to acquire balance 16.75% over a period of time.

Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.


Aurobindo Pharma Share Price

1487.70 -0.80 (-0.05%)
11-May-2026 11:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1877.45
Dr. Reddys Lab 1290.00
Cipla 1332.00
Zydus Lifesciences 945.20
Lupin 2256.50
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×